Skip to main content

Crosstalk in Tumor Microenvironments: Shaping Early Drug and Immunotherapy Strategies

77kviews
Editorial08 January 2026
Editorial: Crosstalk in tumor microenvironments: shaping early drug and immunotherapy strategies

apoptosis-related pathways and reconstructing a risk signature driven by CTSC. Their findings, supported by functional assays confirming CTSC's role in proliferation, migration, and TME remodeling, highlight how malignant cell states and stromal interplay co-evolve to influence immunotherapy resistance. In a third study by Varricchio et al. the authors focused on Hodgkin lymphoma, revealing that FKBP51 expression within CD4⁺ tumor-infiltrating lymphocytes, more than in Hodgkin/Reed-Sternberg cells, was a critical determinant of clinical outcome. Their spatial mapping of TME architecture demonstrated how CD4⁺ rosettes and tumor-associated macrophages (TAMs) contribute to a protumoral niche. Together, these omics-driven studies emphasize that both stromal programs and immune cell spatial patterning function as powerful prognostic dimensions, emerging as integral components of disease classification.In a comprehensive review, Wen et al. (2025) underscore that the nervous system actively tunes the TME. CNS-derived neurotransmitters and neuropeptides can alter immune cell behavior: for example, sympathetic norepinephrine can upregulate PD-1 on immune cells and bolster suppressive macrophages/MDSCs, damping antitumor immunity. Tumors also recruit nerve fibers via neurotrophic factors, reshaping local immunity. Targeting this neuro-immune crosstalk (e.g. with β-blockers) is promising, but redundant pathways and broad neural roles may complicate therapy. In a distinct but for such aspects connected to immune checkpoints several studies explored tumor immunity through the lens of myeloid regulation and TAM-targeted approaches. Wang et al. provided a comprehensive review of Stanniocalcin-1 (STC1) as a phagocytosis checkpoint regulating macrophage activation, polarization, and antigen presentation. By summarizing data showing STC1's involvement in EMT, immunosuppression, and impairment of "eat-me" molecules, Wang et al. underscored the emerging concept that manipulating macrophagetumor interactions is a promising direction for immunotherapy development. These works, taken together, highlight how antibodies and myeloid-modulatory agents represent parallel paths to reprogram immune responses within the TME. Dumut et al. (2025) report that a novel anti-cancer compound, namely disulfiram-derived copper complex (CuET) pharmacologically "ignites" the TME. In colorectal models it turned "cold" tumors hot, driving lymphocyte infiltration and boosting NK/T cell cytotoxicity. CuET upregulated NKG2D ligands on cancer cells, improving immune recognition. CuET transforms the colorectal cancer TME, sustaining NK and T cell cytotoxicity and refining tumor cell recognition through non-conventional activation via the NKG2D/NKG2DL axis. This raises the prospect of repurposing DSF/Cu to enhance immunotherapy. However, careful dosing and validation in diverse tumors are needed.Multiple studies in this issue delve into how specific stromal or immune components influence tumor progression and therapeutic failure. The crosstalk between stromal fibroblasts, immune cells, and malignant cells emerges repeatedly as a dominant theme. The findings across these articles converge on a consistent message: stromal cells are not passive scaffolds but dynamic regulators of cytokine networks, extracellular matrix remodeling, and metabolic rewiring, all of which dictate immune surveillance and drug penetration. Several articles highlight how intrinsic tumor pathways interface with the immune landscape to shape disease trajectory. These works underline a critical emerging concept: cancer cell-intrinsic vulnerabilities often become actionable only when contextualized within TME pressures, and immunotherapy effectiveness cannot be fully predicted without considering both compartments. Collectively, the research gathered in this issue forms a coherent picture: TME complexity is not merely a challenge but an opportunity-one that can be harnessed to design therapies that exploit stromal vulnerabilities, alter immune cell behavior, and overcome tumor evasive strategies.

Looking ahead, several promising directions emerge from the collective insights of this special issue. First, integrating single-cell and spatial transcriptomics into early-stage drug development will be essential to map not only who is present in the TME but how cellular interactions evolve under therapeutic pressure. Second, stromal and macrophage-targeted therapies-highlighted by the STC1 axis and CAF-derived programs-represent a frontier for combination strategies designed to reshape immunologically "cold" tumors into responsive ones. Third, the diversity of OX40-targeting antibodies generated by Rapuano Lembo et al. exemplifies how epitope-specific engineering can unlock new layers of immune activation, suggesting that next-generation immunotherapies may rely on fine-tuned modulation rather than inhibition alone. Finally, the integration of machine learning-derived prognostic signatures into clinical workflows offers a path toward patient-specific immunotherapy design, ensuring that therapeutic strategies are aligned with the underlying ecology of each tumor

805 views

1 citations

ORIGINAL RESEARCH
3 November 2025
Expression and prognostic value of FKBP51 in Hodgkin lymphoma
Silvia Varricchio, 13 more and Massimo Mascolo

2,534 views

1 citations

ORIGINAL RESEARCH
16 July 2025
Identification of CTSC-driven progression in ESCC by single-cell sequencing and experimental validation
Xin Sui, 4 more and Yanru Qin

4,439 views

1 citations

ORIGINAL RESEARCH
14 May 2025
Construction of a stromal cell-related prognostic signature based on a 101-combination machine learning framework for predicting prognosis and immunotherapy response in triple-negative breast cancer
Fanrong Li, 7 more and Shenghua Zhang

9,615 views

9 citations

ORIGINAL RESEARCH
12 February 2025
Diethyldithiocarbamate-copper complex ignites the tumor microenvironment through NKG2D-NKG2DL axis
Daciana C. Dumut, 13 more and Danuta Radzioch

4,746 views

4 citations

ORIGINAL RESEARCH
10 February 2025
Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models
Ying Jin, 7 more and Mark L. Chiu

4,157 views

5 citations

CASE REPORT
27 January 2025
Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review
Genlin Lu, 2 more and Renya Jiang

4,646 views

5 citations

Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in the treatment of advanced colorectal cancer: a systematic review and meta-analysis
were systematically searched for relevant studies. Outcomes including median progression-free survival (mPFS), median overall survival (mOS), overall response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAEs) and ≥grade 3 TRAEs were extracted for further analysis. The risk of bias was assessed by subgroup analysis.Results: 12 articles with 566 patients were identified and subjected to meta-analysis.With regard to survival analysis, the pooled mOS and mPFS were 6.66 months (95%CI 4.85-9.16) and 2.92 months (95%CI 2.23-3.83), respectively. In terms of tumor response, the pooled ORR and DCR were 21% (95%CI 6%-41%) and 49% (95%CI 27%-71%), respectively. The pooled AEs rate and ≥ grade 3 AEs rate were 94% (95%CI 86%-99%) and 44% (95%CI 30%-58%).PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors have shown promising clinical responses in the treatment of colorectal cancer (CRC). Although the incidence of adverse reactions is high, they are generally tolerable.

8,680 views

34 citations

REVIEW
25 November 2024
Stanniocalcin-1 in tumor immunity: acts via macrophages
Lele Wang, 2 more and Weihong Ge

3,712 views

12 citations

Melanoma is a metastatic, drug-refractory cancer with the ability to evade immunosurveillance. Cancer immune evasion involves interaction between tumor intrinsic properties and the microenvironment. The transcription factor E2F1 is a key driver of tumor evolution and metastasis. To explore E2F1's role in immune regulation in presence of aggressive melanoma cells, we established a coculture system and utilized transcriptome and cytokine arrays combined with bioinformatics and structural modeling. We identified an E2F1-dependent gene regulatory network with IL6 as a central hub. E2F1-induced IL-6 secretion unleashes an autocrine inflammatory feedback loop driving invasiveness and epithelial-to-mesenchymal transition. IL-6-activated STAT3 physically interacts with E2F1 and cooperatively enhances IL-6 expression by binding to an E2F1-STAT3-responsive promoter element. The E2F1-STAT3/IL-6 axis strongly modulates the immune niche and generates a crosstalk with CD4 + cells resulting in transcriptional changes of immunoregulatory genes in melanoma and immune cells that is indicative of an inflammatory and immunosuppressive environment. Clinical data from TCGA demonstrated that elevated E2F1, STAT3, and IL-6 correlate with infiltration of Th2, while simultaneously blocking Th1 in primary and metastatic melanomas. Strikingly, E2F1 depletion reduces the secretion of typical type-2 cytokines thereby launching a Th2-to-Th1 phenotype shift towards an antitumor immune response. The impact of activated E2F1-STAT3/IL-6 axis on melanoma-immune cell communication and its prognostic/therapeutic value was validated by mathematical modeling. This study addresses important molecular aspects of the tumor-associated microenvironment in modulating immune responses, and will contribute significantly to the improvement of future cancer therapies.

5,089 views

18 citations